Anthropic Launches Claude Science and Internal Drug-Discovery Programs Targeting Neglected Diseases

Anthropic announced Claude Science on June 30, 2026 — a research workbench built on its Claude models that consolidates more than 60 pre-configured functions for genomics, proteomics, structural biology, and cheminformatics into a single environment for drugmakers. Alongside the product launch, Anthropic revealed it is standing up its own internal early-stage drug-discovery programs focused on 'neglected' diseases — rare genetic disorders and tropical diseases that traditional pharmaceutical and biotech companies avoid because treatments would not be commercially profitable. Eric Kauderer-Abrams, who heads Anthropic's life-sciences efforts, said the dual purpose is 'accelerating scientific discovery' while 'alleviating the burden of disease and aging.' By researching these conditions directly, Anthropic can stress-test its own AI tools against real drug-discovery workflows while addressing diseases that lack commercial appeal — an approach the company says its public-benefit-corporation structure enables. Anthropic has not yet disclosed specific disease targets, funding commitments, or timelines for advancing any candidates to clinical trials.